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Abstract.  Fibroblasts have cell surface sites that medi- 
ate assembly of plasma and cellular fibronectin into 
the extracellular matrix.  Cell adhesion to fibronectin 
can be mediated by the interaction of an integrin 
(oL5/3~) with the Arg-Gly-Asp-Ser (RGDS)-containing 
cell adhesion region of fibronectin.  We have attempted 
to elucidate the role of the otsfll fibronectin receptor in 
assembly of fibronectin in matrices.  Rat monoclonal 
antibody mAb  13, which recognizes the integrin fll 
subunit,  completely blocked binding and matrix as- 
sembly of 125I-fibronectin as well as binding of the 1251- 
70-kD amino-terminal  fragment of fibronectin (70 kD) 
to fibroblast cell layers. Fab fragments of the anti-/~ 
antibody were also inhibitory.  Antibody mAb  16, 
which recognizes the integrin ors subunit, partially 
blocked binding of 125I-fibronectin and  12q-70-kD. 
When cell layers were coincubated with fluorescei- 
nated fibronectin and either anti-13~ or anti-us,  anti-131 
was a more effective inhibitor than anti-o~s of binding 
of labeled fibronectin to the cell layer.  Inhibition of 
~2q-fibmnectin  binding by anti-/31 IgG occurred within 
20 min.  Inhibition of 125I-fibronectin binding by anti-/3t 
Fab fragments or IgG could not be overcome with in- 
creasing concentrations of fibronectin,  suggesting that 
anti-131 and exogenous fibronectin may not compete for 
the same binding site.  No/31-containing integrin bound 
to immobilized 70 kD.  These data indicate that the/31 
subunit plays an important role in binding and assem- 
bly of exogenous fibronectin, perhaps by participation 
in the organization,  regeneration,  or cycling of the as- 
sembly site rather than by a direct interaction with 
fibronectin. 
F 
IBRONECTIN is a dimeric glycoprotein consisting  of 
two similar  250-kD disulfide-bonded  subunits.  Fi- 
bronectin exists in soluble and insoluble forms. Solu- 
ble protameric fibronectin is found at high concentrations  in 
plasma and other bodily fluids and in the conditioned media 
of cultured cells.  Insoluble fibronectin consists of high mo- 
lecular weight disulfide-bonded multimers organized into an 
extracellular  fibrillar  matrix (Mosher,  1980, 1984; Hynes, 
1981; Mosher and McKeown-Longo,  1985; Hedman and Va- 
heri,  1989; Yamada, 1989). 
Insoluble fibronectin mediates cell attachment,  provides a 
substrate for cell migration during embryogenesis and wound 
healing,  and thus is considered the primary functional  form 
of the protein (Ruoslahti,  1988; Thiery et al.,  1989; Col- 
vin,  1989).  A crucial cell attachment site has been local- 
ized  to a  specific  tetrapeptide  sequence, Arg-Gly-Asp-Ser 
(RGDS),  found  in  the  central  region  of each  fibronectin 
subunit (Pierschbacher and Ruoslahti,  1984; Yamada, 1989). 
Cell attachment to fibronectin  is mediated in part by the in- 
teraction of the RGDS site with a specific cell surface fibro- 
nectin receptor (txs~),  a member of the noncovalent hetero- 
dimer integrin  receptor group (Pytela et al.,  1985; Hemler 
et al.,  1987; Hynes,  1987; Takada et al.,  1987; Ruoslahti, 
1988). 
The mechanism by which fibronectin  is incorporated into 
the extracellular matrix is unclear. One proposed mechanism 
involves a disulfde exchange  reaction between the amino- 
terminal  portion  of different  fibronectin  molecules  (Mc- 
Keown-Longo and Mosher, 1984). Transglutaminase-medi- 
ated cross-linking  also promotes insolubilization  (Barry and 
Mosher,  1988, 1989).  Fibronectin insolubilization  and as- 
sembly appear to occur at the cell surface. Dimeric and mul- 
timeric fibronectin  have been localized at the cell surface 
using metabolic and cell surface-labeling techniques (Hynes 
and Destree, 1977; Keski-Oja et al., 1977; Choi and Hynes, 
1979). In vitro and in vivo studies have shown that cell sur- 
face associated fibronectin  consists  of both endogenously 
synthesized cellular fibronectin and circulating plasma fibro- 
nectin  (Oh et al.,  1981; Sekiguchi  et al.,  1986). 
Fibroblast monolayers bind soluble iodinated  plasma and 
cellular  fibronectin  in  a  specific  and  saturable  manner 
(McKeown-Longo and Mosher,  1983; Allio and McKeown- 
Longo,  1988). Initially, fibronectin  is reversibly bound and 
soluble in 1% deoxycholate but with longer incubation times 
fibronectin  forms deoxycholate insoluble disulfide-bonded 
multimers.  Pulse-chase and saturation kinetic  experiments 
indicate that the deoxycholate soluble pool is the precursor 
of the insoluble pool (McKeown-Longo and Mosher, 1983; 
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ported by microscopic studies which show that fluorescein- 
and  gold-labeled  fibronectin  localize  initially  in  clusters 
along the edge of the cell that at later times become rear- 
ranged into long fibrillar  structures  along the cell surface 
(McKeown-Longo and Mosher,  1983; Pesciotta-Peters and 
Mosher,  1987). ~25I-fibronectin does  not bind  specifically 
to  isolated  matrices  and  does  not  form disulfide-bonded 
or transglutaminase  cross-linked multimers in the absence 
of cells  (McKeown-Longo and  Mosher,  1983; Barry and 
Mosher,  1988). 
The importance of cells in mediation of fibronectin matrix 
assembly is supported by the observation that transforming 
growth factor-beta and agents which modulate intracellular 
cAMP levels influence fibronectin matrix assembly activity 
(Allen-Hoffmann and Mosher, 1987; Allen-Hoffmann et al., 
1988). HT1080 fibrosarcoma cells bind and assemble exoge- 
nous fibronectin into a matrix only after treatment with dexa- 
methasone (McKeown-Longo and Etzler,  1987). 
Three experimental results suggest that exogenous soluble 
fibronectin binding to cell monolayers is mediated by the 
fibronectin amino-terminal region rather than the RGDS cell 
attachment site. First,  70- and 27-kD amino-terminal frag- 
ments, lacking the RGDS cell attachment site, bind to fibro- 
blast monolayers and compete with exogenous fibronectin 
for binding  (McKeown-Longo and Mosher,  1985; Quade 
and McDonald,  1988). Second, the 70-kD amino-terminal 
fragment (70 kD) and a monoclonal antibody to the fibronec- 
tin aminoterminal  region block  endogenously  synthesized 
fibronectin matrix assembly (McDonald et al., 1987). Third, 
3T3 cells, infected with a retroviral expression vector con- 
taining cDNA that encodes for fibronectin lacking the ami- 
no-terminal half, synthesize and secrete recombinant trun- 
cated fibronectins referred to as deminectins.  Deminectin 
homodimers are not incorporated into the matrix (Schwarz- 
bauer et al., 1987). Exogenous fibronectin binding and ma- 
trix assembly mediated by the amino-terminal region rather 
than the RGDS-containing cell adhesion domain led to the 
proposal  of a distinct "matrix assembly receptor"  on sub- 
strate attached cells (McKeown-Longo and Mosher,  1983, 
1985, 1989). 
There are also data that suggest involvement of both the 
fibronectin cell  adhesion domain and the t~/~) fibronectin 
cell  adhesion  receptor  in  fibronectin matrix  assembly. A 
105-kD RGDS containing cell binding fragment and a mono- 
clonal antibody that recognizes the fibronectin cell attach- 
ment site block matrix assembly of endogenously synthe- 
sized fibronectin (McDonald et al., 1987).~ Rat monoclonal 
antibodies mAb 16 and mAb 13, which bind to the ct5 and 
~  subunits, respectively, of the human fibroblast fibronec- 
tin receptor  complex,  inhibit fibronectin matrix  formation 
when incubated with freshly seeded human WI38 fibroblast 
cultures (Akiyama et al.,  1989). 
In this paper, we have examined the effect of monoclonal 
antibodies specific for the integrin ct5 subunit (mAb 16) and 
the integrin/~ subunit (mAb 13) on exogenous fibronectin 
and 70-kD binding to fibroblast monolayers in short-term as- 
1. McKeown-Longo and Mosher (1985) reported that cell adhesion frag- 
ments up to 0.25 #M did not inhibit binding of exogenous fibronectin. We 
find that higher concentrations similar to those used by McDonald et al. 
(1987) are inhibitory (Fogerty, E  J., and D. E  Mosher, unpublished data). 
says. We wished to learn if these antibodies block binding 
and assembly of exogenous fibronectin, about the kinetics of 
the inhibition, and especially whether the antibodies block 
binding of the 70-kD fragment. These studies indicate that 
the/31 protein plays an important  although unclear role in 
matrix assembly. 
Materials and Methods 
Materials 
Human neonatal foreskin fibroblasts were from a locally established strain 
(Dr. Lynn Allen-Hoffmann, University of Wisconsin) and were studied be- 
tween passages 10 and 20. Human osteosareoma cells (MG-63) were from 
the American Type Culture Collection (Rockville, MD). Cathepsin D, cy- 
cloheximide, soybean trypsin inhibitor, chymotrypsin (type II), PMSF, BSA 
(fraction V),  lactoperoxidase  (from bovine milk),  deoxycholate,  cyanogen 
bromide, gelatin (from swine skin), and Sepharose CL-4B-200 were from 
Sigma Chemical Co. (St. Louis, MO). Trypsin was from ICN Biomedicals, 
Inc.  (Irvine,  CA).  Octyl-/~-D-thioglucopyranoside and protein A-agarose 
were purchased from Calbiochem-Behring Corp. (La Jolla, CA). Heparin- 
Sepharose was from Pharmacia (Piscataway,  NJ). Carder-free I~iodine and 
Na2S~Cr04 were from Dupont (Hoffmann Estates, IL). Gelatin-Sepharose 
was pro'pared in this lab following a published procedure (Cuatrecasas, 1970). 
Acrylamide/bis-Acrylamide (37.5:1  solution) was purchased from Ameri- 
can Research Products Corp.  (Solon, OH).  Reagents for SDS-PAGE were 
from Bio-Rad Laboratories (Richmond, CA). 
Antibodies 
MAb 16 and mAb 13 have been previously described (Akiyama et al., 1989; 
Matsuyama et al.,  1989). Rabbit polyclonal anti-~5~l was a generous gift 
from Dr. Erkki Ruoslahti (La Jolla Cancer Research Foundation, La Jolla, 
CA). Mouse monoclonal antibody J143 was a gift from Dr.  Lloyd J. Old 
(Memorial Sloan-Kettering Cancer Center, New York)  and is specific for 
the integrin t~3 subunit (Hemler et al.,  1987;  Kantor et al.,  1987). Mouse 
monoclonal antibody PIB5 was a gift from Drs. Elizabeth Wayner and Wil- 
liam  Carter  (Fred  Hutchinson  Cancer  Research  Center,  Seattle,  WA). 
Monoclonal antibody P1B5 is specifc for integrin ot3fll and was previously 
shown to block tx3fll function (Wayner and Carter,  1987;  Takada et al., 
1988). Mouse monoclonal antibodies LM142 and LM609 were gifts from 
Dr. David A. Cheresh (Research Institute of Scripps Clinic, La Jolla, CA). 
Monoclonal antibody LM142 is directed against the vitronectin receptor tx 
subunit (Cheresh and Harper,  1987). Monoclonal antibody LM609 is c~v/~3 
complex  specific  and  was  previously  shown  to  block  art3  function 
(Cheresh and Spiro,  1987). 
Experimental Procedures 
Cell Culture. Human foreskin fibroblasts were cultured in 50% Ham's F-12 
(Gibco Laboratories, Grand Island, NY), 50 % Dulbecco's modified Eagle's 
medium (Gibco Laboratories),  supplemented with  10%  fetal calf serum 
(Hazleton, Denver, PA). Human osteosarcoma MG-63 cells were cultured 
in Eagle's minimum essential media (Gibco Laboratories) supplemented 
with 5% fetal calf serum. 
Fibroneeffn and lqbroneetin  Fragments.  Human plasma  fibronectin 
was purified as previously described from a fibronectin- and fibrinogen-rich 
by-product of Factor VRI production (Mosher and Johnson, 1983). The 70- 
kD amino-terminal, gelatin-binding fragment of fibronectin (70 kD) was 
purified from cathepsin D  digests of fibronectin as previously described 
(McKeown-Longo  and Mosher,  1985) with the following modifications. 
Digestion was allowed to proceed for 3 h at 37°C and an additional 2 h at 
22°C. The pH of the digest was immediately raised to 7.4 with the addition 
of 0.5 M Tris, and the neutralized digest was directly applied to a gelatin- 
Sepharose column. After elution with 3 M guanidine hydrochloride, 70-kD 
fragment was separated from a contaminating 40-kD gelatin-binding break- 
down product on a G-100 gel filtration column run in TBS (150 mM NaCI/ 
10 mM  Tris,  pH  7.4).  Purity  of fragments was assessed by SDS-PAGE 
(Laemmli,  1970).  Fragment aliquots were stored at  -70"C. 
Iodination of Fibronectin and 70 kD. Iodination of fibronectin and 70 
kD was performed using the chloramine T method as previously described 
(McKeown-Longo and Mosher, 1983, 1985). The specific activities of 12~I- 
fibronectin and 1251-70 kD were typically ~350 #Ci/mg. Purity of labeled 
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by autoradiography. 
12Sl-Fibronectin and  IZ~l-70 kD  Binding Assays. Human  foreskin 
fibroblasts were seeded 6-8  x  104 cells per 2-cm  2 well (24-well plates; 
Becton Dickinson Labware, Lincoln Park, NJ) and were used in binding 
assays 2--4 d after seeding when the cells reached confluency as assessed 
by phase microscopy. Medium (0.5 ml) containing 0.2% BSA, radioligand, 
and sometimes unlabeled ligand and/or antibody was added to the cell layers 
and incubated at 37"C for the indicated times. Free ligand was separated 
from bound by removing the binding mix and washing the cell layers thrice 
with cold PBS (150 mM NaCI/20 mM phosphate, pH 7.4). Then ceU layers 
were either solubilized in 1 N NaOH to determine the total amount of la- 
beled ligand associated with the cell layer or separated into fractions soluble 
and insoluble in 1% deoxycholate (Pool I/II assay) as previously described 
(McKcown-Longo and Mosher, 1983).  In long-term (6 h) binding assays, 
cycloheximide (10 #g/ml), was added to eliminate possible effects of en- 
dogenously synthesized fibronectin. 
Cell Adhesion Assay. Cell  adhesion assays were performed using a 
method similar to that of Wayner and Carter,  (1987).  Microtiter 96-well 
polystyrene plates (model 3596; Costar, Cambridge, MA) were coated with 
fibronectin or heat-denatured BSA (200/~1 protein solution in PBS per well, 
5/~g protein/ml). Plates were coated for 1.5-4.5 h at 37°C and then blocked 
with 200/~1  of 1% heat denatured BSA in PBS for 1-2 h at 37°C. Plates 
were washed with PBS several times after blocking in BSA. 
Fibroblasts in 75-cm  2 dishes (Becton Dickinson Labware) were labeled 
with Na~SlCrO4  (50 t~Ci/mi)  for 2-4 h  at 37°C in medium. Ceils were 
released by incubating for 5 rain at 370C in a mixture of 2 ml trypsin/PBS 
(0.05%  wt/voi) and 2 ml EDTA/PBS (0.02%  wt/vol). Trypsinization was 
stopped with the addition of 4 ml medium containing 10% FCS. The cells 
were pelleted and then resuspended in Ham's F-12 containing 0.2% BSA. 
Suspended cells (0.8-1.3  x  10  s cells/ml) were incubated 30 min at room 
temperature with antibody or media alone. Aliquots (0.2 ml) of each incuba- 
tion mixture (•1.6-2.5  x  104 cells) were pipetted into coated microtiter 
wells, and cells were allowed to adhere to the fibronectin or BSA coated 
surface for 15-30 min at 37°C. Nonadherent cells were removed by washing 
with PBS. Adherent cells were dissolved in 1 N NaOH and quantitated in 
a gamma counter. 
Incorporation of  Fluoresceinated Fibronectin into Cell Layers and Lo- 
calization of Anti-~dl (mAb 13) and Anti-aj (mAb 16) IgG. Fluorescei- 
hated fibronectin (FITC-fibronectin) was prepared as previously described 
(McKeown-Longo and Mosher,  1983).  Fibroblasts were seeded onto 13- 
ram glass coverslips (No. 2; Ernest Fullam, Inc., Schenectady, NY) placed 
in 2-cm  2 wells at 1 x  10  ~ cells per well, and allowed to attach overnight. 
The next day, serum-containing media was replaced with 0.5 mi of Ham's 
F-12 medium containing 0.2% BSA and 20/zg/ml FITC-fibronectin either 
alone or supplemented with 5  ~g/ml anti-/31  or anti-ors IgG.  Cell layers 
were incubated for 60 min at 370C, then rinsed three times with PBS, and 
fixed for 30 min at room temperature in 0.1 M phosphate buffer, pH 7.4, 
containing 3.5 % paraformaldehyde. The distribution of integrin ors and/~1 
subunits in cells incubated with anti-us and -/~l  IgGs was visualized by 
immunofluorescence. After fixation, cells that had been incubated with 
FITC-fibronectin plus antibody were rinsed and then incubated 45 min at 
room temperature with a  1:16 dilution of rhodamine conjugated rabbit 
anti-rat IgG (Sigma Chemical Co.) in  1%  BSA/PBS. The distribution of 
integrin ors and ~  subunits in cells not treated with antibodies was exam- 
ined  using  cell  layers  that  had  been  previously  incubated with  FITC- 
fibronectin alone. These cell layers were incubated 60 rain after fixation 
with anti-~s or anti-/3t  (5 #g/ml) in PBS containing 1% BSA followed by 
a 45-min incubation with the rhodamine conjugated rabbit anti-rat IgG. 
Coverslips were rinsed with PBS and mounted on glass slides in glycerol- 
gelatin (Sigma Chemical Co.). Slides were viewed and photographed on a 
Nikon microscope equipped with epifluorescence and phase contrast. Cells 
were photographed using Ektachrome 400 film (Kodak, Rochester, NY). 
Surface  Labeling and  Extraction  of Cells.  Fibroblasts  grown  to 
confuence in 75-cm  2 dishes were detached with 1 mM EDTA in PBS for 
30-60 rain and collected by centrifugation. Cells were washed once with 
PBS, and resuspended to 1.0 x  10  s cells/ml in PBS with 1 mM MgCI2. All 
subsequent steps were done at 4°C. The suspended cells were radiolabeled 
according to the procedure of Lebien et al. (1982) using 1 mCi 12SI-sodium 
iodide and 0.2 mg/ml of lactoperoxidase per l0  s cells. Cells were lysed by 
adding 1 ml lysis buffer (50 mM Tris, pH 7.4,  150 mM NaCI, 50 mM oc- 
tyl-/~-o-thioglucopyranoside, 1 mM MgC12,  1 mM CaC12,  1 mM MnCI2, 
3 mM PMSF) and incubating 30 rain on ice. Detergent-insoluble material 
was removed by centrifugation at 27000 g  for 30 min. 
Affinity Chromatography. The c~s~l fibronectin cell adhesion receptor 
was isolated following the methods of Pytela et al. (1985,  1987).  The 120- 
kD chymotryptic cell binding fragment of  fibronectin was prepared as previ- 
ously described (Pierschbacher et al.,  1981). Briefly,  50 mg of fibronectin 
was diluted to a final concentration of 2 mg/ml in 50 mM Tris, pH Z4, con- 
taining  1  mM  CaC12. Fibronectin was  digested 75  rain  at  37°C  with 
chymotrypsin (type II; Sigma Chemical Co.) at a final concentration of 20 
/~g/ml. The reaction was stopped with the addition of PMSF (final concen- 
tration of 2 mM) and soybean trypsin inhibitor (final concentration of 200 
#g/ml).  The  120-kD  fragment  was  purified  by  gelatin-Sepharose and 
heparin-Sepharose chromatography. Approximately 9  mg of the 120-kD 
fragment was coupled to 25 ml of CNBr-activated Sepharose (Cuatrecasas, 
1970).  70 kD was prepared as described above, and "-25 mg was coupled 
to 60 ml of CNBr-activated Sepharose. Polyclonal rabbit antibodies to 70 
kD were passed over the column and recovered with 0.2 M glycine, pH 2.3, 
to verify that 70 kD had coupled to Sepharose. 
Batch adsorption was carried out by mixing 1 ml of the iodinated cell 
lysate with 3 ml of 120-kD Sepharose or 2.5 ml of 70-kD Sepharose over- 
night at 4°C. The slurries were then poured into columns and allowed to 
settle and equilibrate to room temperature. The unbound material was col- 
lected, and the column beds were then washed with 25 mM octyl-/3-D-thio- 
glucopyranoside in 150 mM NaC1/50 mM Tris, pH 7.4. Bound material was 
eluted with 10 mM EDTA in 25  mM octyl-/3-D-thioglucopyranoside/150 
mM NaCI/50 mM Tris, pH 7.4.70-kD Sepharose was further eluted with 
0.2 M glycine, pH 2.3. Unbound and bound fractions were subjected to im- 
munoprecipitation and analyzed by SDS-PAGE and autoradiography. 
Imraunoprecipitatlons. Immunoprecipitations were carried out as de- 
scribed (Kessler, 1981; Harlow and Lane, 1988).  Samples were precleared 
by incubating with 25 #g/ml preimmune rabbit IgG for 60 min at 4°C fol- 
lowed by a 60-min incubation with protein A-agarose. The supernatant was 
then removed to a new tube and incubated overnight with 50-100/zg/ml rab- 
bit anti-cts/3t  IgG. The next day, antigen-antibody complexes were precipi- 
tated by incubating 60 min with protein A-agarose. The resin was allowed 
to settle, supernatant was removed, and resin was washed five times with 
1 ml of 1%  Triton X-100/PBS.  Antigen-antibody complexes were eluted 
with 10%  SDS in 9 M  urea and subjected to SDS-PAGE. 
Gel Electrophoresis. SDS-PAGE was performed using 8%  separating 
and 3.3%  stacking gels (Laemmli, 1970).  14C-methylated protein standards 
(Amersham Corp.,  Arlington Heights,  IL)  were myosin (Mr 200,000), 
phosphorylase-b (Mr 92,500), bovine serum albumin (Mr 69,000), ovalbu- 
min (Mr 46,000),  carbonic anhydrase (Mr  30,000).  Dried gels were ex- 
posed to Kodak XAR-2 film for 4 d. 
Results 
Effect of Monoclonal Antibodies Specific for the 
Human Fibroblast Fibronectin Receptor re5 Subunit 
andS1 Subunit on Binding of Exogenous Fibronectin, 
Binding of the Amino-terminal  70-kD Fragment, and 
Initial Attachment of Suspended Fibroblasts to 
a Fibronectin Substratum 
Anti-ct5  partially  blocked  125I-fibronectin  and  12sI-70 kD 
binding to fibroblast cell layers without gross effects on cell 
morphology (Fig.  1 A). Approximately 40-60%  of the 1251- 
fibronectin  and  1251-70 kD  specific  binding  was  blocked 
with 2.0/zg/ml IgG. Higher concentrations, up to 20/~g/ml, 
did not inhibit more.  Anti-as inhibited initial fibroblast at- 
tachment to fibronectin with a dose response similar to that 
observed for inhibition of binding (Fig.  1 A). 
In contrast,  anti-~  completely  blocked binding of both 
125I-fibronectin and t2sI-70 kD to cell layers and blocked ini- 
tial cell attachment to a fibronectin substratum (Fig.  1 B). 
Similar inhibition of l:sI-fibronectin  and 1251-70 kD binding 
by anti-/31 and anti-a~ was seen with MG-63 osteosarcoma 
cells  (data not shown). 
We examined what effect these antibodies had on exoge- 
nous FITC-fibronectin binding to cultured fibroblast mono- 
layers (Fig. 2). The fluorescence microscopic data corrobo- 
rated the binding study results.  Coincubation of fibroblast 
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Figure 1. Effect of anti-c~5 and -/3, antibodies on binding of fibro- 
nectin and 70-kD fragment and on cell attachment to a fibronectin 
substratum.  Confluent monolayers of human  foreskin fibroblasts 
('~2.0 x  105 cells) grown in 2-cm  2 wells were incubated in 0.5 ml 
of Ham's I=-12 media containing 0.2% bovine albumin and either 
~2~I-flbronectin (300,000 cpm,  246  ng)  or  ~2~I-70 kD  (380,000 
cpm, 200 ng) alone or in the presence of increasing concentrations 
of anti-~ (A) or anti-/~ (B) for 60 min at 37~C. Cell layers were 
then solubilized in 1 N NaOH, and the radioactivity was counted. 
~:~I-fibronectin binding (open squares)  and ~I-70 kD binding (open 
circles) are expressed as percent of control binding, the amount of 
radioligand that bound specifically to cell layers in the absence of 
antibodies. Nonspecific binding, measured in the presence of 500 
/~g/mI labeled fibronectin or 15 t~g/ml unlabeled 70 kD, was sub- 
tracted from controls as well as antibody-treated binding counts be- 
fore calculating the percent of control binding values. Control cell 
layers bound 4,600 cpm (2.4 ng) of ~51-70 kD and 3,900 cpm (3.2 
ng) of '~I-fibronectin.  Nonspecific binding was 30% for the  ~I- 
fibronectin binding assay, and 42% for the ~asI-70-kD  binding as- 
say. t~I-fibronectin binding points represent the average of dupli- 
cate determinations and the error bar depicts the range. ~51-70-kD 
binding points represent the average of triplicates, and the error bar 
indicates the standard deviation. Cell attachment (solid triangles) 
to fibronectin-coated dishes was measured in the absence or pres- 
ence of increasing concentrations of anti-c~5 (A) or anti-/3t (B) fol- 
lowing procedures described  in Materials  and Methods.  Data are 
expressed as percent  of control  cell adhesion where control  cell 
adhesion represents the number of cells that adhered to fibronectin 
monolayers with anti-fl~ IgG and FITC-fibronectin dramati- 
cally reduced amounts of bound FITC-fibronectin (compare 
Fig. 2 C [FITC-fibronectin +  anti-ill IgG] with 2 D  [FITC- 
fibronectin only]). Instead of long streaks of bound protein 
along the sides and over cells, dots of FITC-fibronectin were 
arranged in a linear distribution along the edges of the cells. 
There also were differences in/3~  distribution in antibody- 
treated and -untreated cells. After a 60-min incubation with 
5/~g/ml of anti-fit IgG, the fl~ subunit was arranged in lin- 
ear streaks whereas fl~ ,appeared more clustered in ceils that 
were  fxed  before  anti-fl~  incubation  (compare Fig.  2  G 
[anti-fit  IgG staining  of live cells]  and  2  H  [anti-fl~  IgG 
staining of fxed cells]). Anti-cq IgG slightly reduced FITC- 
fibronectin incorporation into the matrix in a 60-min incuba- 
tion  (compare Fig.  2  A  [anti-as  IgG  +  FITC-fibronectin] 
with 2 B [FITC-fibronectin alone]). The a5 subunit also ap- 
peared to be less clustered in cells that had been incubated 
60 min with 5 tzg/ml anti-as before fixation (compare Fig. 
2  E  [anti-as  IgG staining  of live cells]  with 2  F  [anti-or5 
IgG staining of fixed cells]). 
Staining  of anti-fl~ on fixed cells after a  1-h incubation 
with FITC-fibronectin indicated that/~l distribution closely 
paralleled  exogenous  FITC-fibronectin distribution  (com- 
pare Fig. 2 D  [FITC-fibronectin only] and 2 H  [localization 
of ~, on same cell after fixation]). However, colocalization 
was not absolute (see arrows, Fig. 2, D and H) since FITC- 
fibronectin could be found in places where there was no ~ 
staining. There was no obvious relationship between the dis- 
tribution of FITC-fibronectin and ~5. 
In the phase-contrast micrographs and in routine observa- 
tion of cells by phase microscopy during the various binding 
assays, anti-/~i  and anti-u5 IgGs did not cause gross changes 
in cell morphology during a 60-min incubation. 
Two monoclonal  antibodies  specific for a3fl~, J143  and 
P1B5, failed to block binding of fibronectin or 70-kD frag- 
ment to cell layers (data not shown). Monoclonal antibodies 
to av (LM142) and av~3 (LM609) also were not inhibitory 
(data not shown).  These results  suggested that neither the 
a3~3~ nor  the  Otvf33 integrins  were  involved in  binding  the 
amino-terminal region of fibronectin and provided further 
proof that the observed inhibition of binding by anti-as and 
anti-fl~ was due to specific interactions. 
Time Course of Inhibition of  Binding of 
12~I-Fibronectin by Anti-~1 IgG 
To learn whether inhibition of exogenous fibronectin binding 
by  anti-/~  is  immediate,  fibroblast  monolayers  were  in- 
cubated with ~25I-fibronectin in the presence or absence of 
anti-/~ or excess fibronectin for varying times (Fig.  3).  In- 
hibition of binding was demonstrable 20 rain after the addi- 
tion of radioligand and IgG. In contrast, inhibition by excess 
fibronectin occurred at 3 min. 
in the absence of antibody. Nonspecific background cell adhesion 
to albumin-coated wells was negligible (<1.0%). Each point repre- 
sents the average of triplicate determinations,  and error bars indi- 
cate the standard deviation. 
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-fl~ IgGs on binding of FITC-fi- 
bronectin to cell layers and on the 
distribution of the fibronectin re- 
ceptor  subunits.  The  effect  of 
anti-c~5 IgG on  the  binding  of 
FITC-fibronectin  was  visualized 
by fluorescence microscopy after 
a 60-min incubation of cell layers 
with  20 #g/ml FITC-fibronectin 
alone  (B)  or in the  presence  of 
5  /~g/ml anti-us  IgG (A). The 
cell layers were fixed and the dis- 
tribution  of c~5 on cells exposed 
to anti-c~5 during the  1-h incuba- 
tion (E) or on cells reacted with 
anti-c~5 after fixation (F) was de- 
termined  with  a  rhodamine-la- 
beled  second  antibody.  Corre- 
sponding phase fields are shown 
in  (/)  and  (J).  The  effect  of 
anti-/~t  IgG on  the  binding  of 
FITC-fibronectin  was visualized 
after a 60-min incubation of cell 
layers with 20/~g/ml FITC-fibro- 
nectin alone  (D) or in the pres- 
ence of 5/~g/ml anti-/~ IgG (C). 
The cell layers were fixed and dis- 
tribution  of ~  on cells  exposed 
to anti-/3~ IgG during the  1-h in- 
cubation  (G) or on cells reacted 
with  anti-/3~ IgG  after  fixation 
(H) was determined with a rhoda- 
mine-labeled  second  antibody. 
Corresponding  phase fields are shown in (K) and (L). Arrowheads mark places that contain  FITC-fibronectin (D) but lack 131 staining 
(H). Bar,  1 #m. 
Effect of  Anti-~, Fab Fragments on Binding of 
~zJl-l~bronectin and x2q-70 kD to Fibroblast Cell 
Layers and on Fibroblast Attachment to a 
Fibronectin  Substratum 
Monovalent Fab fragments were tested to rule out the possi- 
bility  that  inhibition  of fibronectin and  70  kD  binding  at 
37°C  by anti-/~  IgG was the indirect result of changes in 
membrane organization associated with receptor clustering 
induced by the bivalent IgG. A longer incubation time (6 h) 
was used so that inhibition of t25I-fibronectin  incorporation 
into deoxycholate-insoluble matrix (pool II) could be quan- 
tified.  Anti-/3~  Fabs blocked ~2~I-fibronectin and  t251-70 kD 
binding to fibroblast cell layers and ~25I-fibronectin accumu- 
lation in Pool II (Fig. 4). Anti-fit Fabs also inhibited initial 
cell  attachment  to  a  fibronectin  substratum  (Fig.  4).  No 
changes in cell morphology were detected by phase-contrast 
microscopy after a  6-h incubation with anti-/3~ Fabs. 
Increasing Concentrations of Exogenous Fibronectin 
Do Not Decrease the Inhibitory Effect of  Anti-/~l 
Fab Fragments 
If anti-fit  Fabs and exogenous fibronectin were competing 
for the same binding site, then one might expect increasing 
concentrations  of fibronectin  to  eventually  overcome  the 
anti-/~l  Fabs inhibitory effect.  Fig.  5  compares binding of 
fibronectin in Pool I and accumulation of fibronectin in Pool 
II measured in the absence or presence of anti-fl~ Fabs. In- 
creasing concentrations  of exogenous fibronectin up to 30 
/xg/ml, a  concentration previously shown to occupy >50% 
of matrix  assembly  sites  (McKeown-Longo and  Mosher, 
1983),  failed to overcome the inhibitory effect of 5  #g/ml 
anti-/3~ Fabs.  This was true for both fibronectin binding in 
Pool I and its accumulation in Pool II. Similar results were 
obtained with anti-/3t  IgG (data not  shown). 
Affinity Chromatography  of  Extracts of  Surface-labeled 
Cells on Immobilized l~'bronectin 120-kD Cell 
Attachment Fragment and on Immobilized Fibronectin 
70-kD Amino-terminal Fragment 
The fact that monoclonal antibodies specific for fl~ and, to 
a lesser extent, or5 subunits of the fibronectin cell adhesion 
receptor inhibited 70 kD binding prompted us to examine 
whether or not ets/3t or another/~l-containing integrin inter- 
acts with 70 kD. Detergent extracts of surface-labeled fibro- 
blasts were subjected to affinity chromatography on either 
immobilized 120-kD cell attachment fragment or immobi- 
lized 70 kD. Bound/3~-containing  integrin was detected by 
immunoprecipitation  using  purified  human placental  c~fl~ 
polyclonal antibodies.  Immunoblotting studies showed that 
these  antibodies  react primarily with  the  fit  subunit  (data 
not shown). 
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Figure 3. Time course of inhibition with anti-~, IgG of ~5I-fibro- 
nectin binding to cell layers. Confluent monolayers of human fibro- 
blasts were washed once with 50% DME/50% Ham's F-12 contain- 
ing 0.2% BSA and 25 mM Hepes, pH Z4 (binding medium). Cell 
layers were then incubated at 37°C for indicated lengths of time in 
0.5 ml binding medium containing ~zsI-fibronectin (800 ng, 300,000 
cpm) alone (solid triangles),  plus 500/~g/ml unlabeled fibronectin 
(open circles),  or 5  /~g/ml anti-fl~  IgG (open squares).  Binding 
was stopped by removing the binding medium, and cell layers were 
washed three times with cold PBS, solubilized in 1.2 ml 1 N NaOH, 
and counted. The total cpm bound for each treatment are plotted 
versus length of incubation with radioligand. Each point represents 
the average of duplicate determinations, and the error bars repre- 
sent the range. 
Immunoprecipitation  of  the  120  kD-Sepharose-bound 
fractions (Fig.  6, lanes 5 and 6) with rabbit polyclonal anti- 
o~5fll showed  two  iodinated  polypeptides  migrating  at  140 
and  120 kD under nonreducing  conditions presumably cor- 
responding to the ors and fll subunits of the receptor. When 
the same volume of labeled cell extract from the same iodi- 
nated cell preparation was incubated with 70 kD-Sepharose, 
no specifically bound ~-containing integrin was detected in 
either the fractions eluted with  10 mM EDTA (Fig. 6, lanes 
11 and 12) or in a subsequent wash of the column with 0.2 M 
glycine,  pH  2.3  (not  shown).  Similarly,  no  fl~-containing 
integrins  were  detected  when  placental  detergent  extracts 
were chromatographed  on 70 kD-Sepharose  and then im- 
munoblotted  with  rabbit  polyclonal  anti-o~5~  (data  not 
shown). 
Discussion 
Antibodies to the/~t  and,  to a  lesser extent,  or5 subunits of 
the fibronectin receptor blocked binding of the 70-kD amino- 
terminal fragment of fibronectin and binding of exogenous 
plasma fibronectin to monolayers of fibroblasts and its incor- 
poration into extracelhlar matrix.  The ability of both IgGs 
to inhibit fibronectin and 70 kD binding paralleled their abil- 
ity to inhibit the initial attachment of suspended fibroblasts 
to a  fibronectin  substratum.  Monovalent Fab fragments of 
anti-fl~  also  inhibited  fibronectin  and  70  kD  binding  sug- 
gesting that inhibition of ligand binding is not a nonspecific 
effect due to receptor clustering  induced by bivalent IgG. 
Anti-/~t  IgG (5/zg/ml) blocked FITC-fibronectin binding 
to cell layers whereas anti-o~5 IgG was much less effective. 
In contrast,  Akiyama et al.  (1989) found significant inhibi- 
tion of extracellular fibronectin matrix accumulation with as 
little  as  1  t~g/ml of anti-ct~  IgG when  human  embryonic 
lung fibroblasts (WI38 ceils) were plated in the presence of 
the  antibody  and  incubated  an  additional  24  h.  The  dis- 
crepancy may be related to differences in the assay. In the 
assay described in this paper, we examined the ability of anti- 
or5 to block binding of exogenously supplied FITC-fibronec- 
tin  during  a  60-min  incubation  by  using  human  foreskin 
fibroblasts that have been allowed to attach and spread in the 
absence of antibody. Most of the assembly is probably at the 
ends  of  already  established  fibrils  (Barry  and  Mosher, 
1989). 
The finding that anti-/~t  more effectively inhibited  fibro- 
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Figure 4.  Effect of anti-#~  Fab fragments on t25I-fibronectin and 
~251-70 kD binding to cell layers and on cell attachment to fibro- 
nectin-coated dishes.  Confluent monolayers of human fibroblasts 
were incubated with 0.5 ml Ham's F-12 media containing 10 ttg/ml 
cycloheximide, 0.2% BSA, and 1251-70 kD (160 rig, 300,000 cpm) 
or 125I-fibronectin (220 rig, 300,000 cpm) alone or in the presence 
of increasing concentrations of anti-/~t Fabs for 6 h at 37°C. Bind- 
ing medium was then removed, and cell layers were washed three 
times with cold PBS.  Cell layers incubated with 1251-70 kD were 
solubilized in 1 N NaOH, and the radioactivity was counted. Cells 
incubated with ~25I-fibronectin  were extracted in 1% deoxycholate, 
and the amounts of fibronectin bound in the deoxycholate-soluble 
Pool I and deoxycholate-insoluble Pool II were determined as de- 
scribed in Materials and Methods.  1251-70 kD binding (open cir- 
cles), and  ~25I-fibronectin binding in Pool I (open triangles)  and 
Pool II (solid triangles) are expressed as the percent of control bind- 
ing (see Fig.  1).  In this experiment, the  t251-70 kD control cells 
bound 2,260 cpm (1.20 rig), and the '25I-fibronectin control cells 
bound 3,990 cprn (3.0 rig) in Pool I and 1,800 cpm (1.3 rig) in Pool 
II. Nonspecific binding was measured in the presence of 500/zg/ml 
unlabeled fibronectin or 25  #g/ml unlabeled 70 kD.  Nonspecific 
binding was 22 % of total binding for Pool I fibronectin binding, 
13 % for Pool II fibronectin binding, and 25 % for 70 kD binding. 
Each point represents the average of duplicate determinations and 
the error bars indicate the range. Cell adhesion (open squares) was 
measured as described in Fig. 1. Each point represents the average 
of triplicate determinations and is expressed as a percent of control 
cell adhesion to fibronectin in the absence of antibody. 
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Figure 5. Effect of anti-/~t Fab fragments on fibronectin binding in 
Pools  I  and  II in  the  presence  of increasing  concentrations  of 
fibronectin. Confluent monolayers of  fibroblasts were incubated 7 h 
in 0.5 ml of F-12 media containing 0.2% BSA, 25 mM Hepes, pH 
7.4, and 10/xg/ml cycloheximide (binding media) plus varying con- 
centrations  of ~25I-fibronectin (80,000 cpm//~g) either  alone or in 
combination with 5/zg/ml anti-Bj Fabs. Binding medium was then 
removed, and cell layers were washed three times with cold PBS, 
and extracted with 1% deoxycholate as described in Materials and 
Methods.  The graph shows specific  ng of fibronectin bound  in 
Pool I in the absence of Fabs (open circles) and in the presence of 
Fabs (open squares)  and the ng of fibronectin accumulated in Pool 
II in the absence of Fabs (solid circles) and in the presence of Fabs 
(solid squares).  Each point represents the average of duplicate de- 
terminations. 
nectin and 70 kD binding than did anti-or5 suggested possi- 
ble involvement of other t~ chains.  Antibody blocking and 
affinity chromatography data suggest that integrin ot3~  is a 
low affinity receptor for fibronectin and also a receptor for 
other ligands (Wayner and Carter, 1987; Wayner et al., 1988). 
The site on fibronectin that t~3~1 binds is not known though 
it appears not  to bind to  120-kD  fibronectin fragment or 
fibronectin affinity columns at physiological salt concentra- 
tion (Wayner and Carter,  1987;  Hynes et al.,  1989;  Plante- 
faber and Hynes, 1989). Two monoclonal antibodies specific 
for ot3/~, J143 and P1B5, failed to block fibronectin and 70 
kD binding to fibroblast cell layers. Since integrin ~tv, in as- 
sociation with a novel B subunit (fix), has been shown to pro- 
mote cell attachment to fibronectin in addition to vitronectin 
(Cheresh  et  al.,  1989),  we  examined  whether  antibodies 
specific for cry or otvB3 complex inhibited binding of 70 kD. 
Two monoclonal antibodies, LM142, which is directed to the 
ct subunit of the vitronectin receptor (Cheresh and Harper, 
1987),  and LM609,  which is directed to the uv/~3 complex 
(Cheresh and Spiro, 1987), also failed to block 70 kD bind- 
ing  to  fibroblast cell  layers.  Studies  are ongoing to learn 
whether other available antiintegrin monoclonal antibodies 
are inhibitory. 
Inhibition of fibronectin binding  by anti-B~ was demon- 
strable 20 min after the simultaneous addition of ligand and 
antibody. This result correlates well with the reported time 
Roman et al.  (1989) found that it took another monoclonal 
antibody specific for u5/31 (P1F8)  to reverse colocalization 
of the fibronectin receptor with a fibronectin-containing ma- 
trix at the immunofluorescence level. In their study fibronec- 
tin-o~sB~ interactions were disrupted within 30 min after the 
addition of P1F8. 
Figure 6. Autoradiograph ofiodinated  cell sur- 
face  proteins  immunoprecipitated  by  rabbit 
anti-txs~t  after chromatography  on  120  kD- 
or 70 kD-Sepharose.  Detergent  extracts pre- 
pared  from  surface-labeled  human  foreskin 
fibroblasts were subjected to affinity chroma- 
tography on either immobilized 120-kD cell at- 
tachment fragment or immobilized fibronectin 
70-kD amino-terminal fragment. Total cell ly- 
sate,  unbound  fraction  and  eluted  fractions 
were  immunoprecipitated  with  a  polyclonal 
anti-ctsB~ which  recognizes  primarily the  /~t 
subunit and immunoprecipitates  ~-containing 
integrins.  The  immunoprecipitated  antigens 
were fractionated on SDS PAGE (8.0%) under 
nonreducing  conditions.  Lane  1,  total lysate 
(starting material);  lane 2,  120 kD-Sepharose 
unbound;  lanes  3-7,  fractions  eluted  with  10 
mM EDTA from 120 kD-Sepharose; lane 8, 70 
kD-Sepharose unbound;  lanes 9-12, fractions 
eluted with 10 mM EDTA from 70 kD-Sepha- 
rose. The c~5 and/~ subunits are indicated on 
the  gel by the  upper and  lower  arrowheads, 
respectively. 
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unable to overcome inhibition by anti-B~ Fabs of fibronec- 
tin binding.  One explanation of this result is that anti-/3~ 
Fabs have a much higher affinity for the receptor than does 
fibronectin.  A  second explanation is  that fibronectin and 
anti-/3~ Fabs do not share the same binding site. 
The discovery that a monoclonal antibody to the integrin 
B~ subunit could block ~2~I-70 kD binding to cell monolay- 
ers prompted us to examine whether any Bt-containing in- 
tegrins bound to  the  immobilized 70-kD  amino-terminal 
fragment. We were unable, however, to demonstrate binding 
of a Bt-containing integrin to 70 kD-Sepharose under con- 
ditions which resulted in the binding of o~sB~ to immobi- 
lized cell adhesion fragment. 
We should like to present three possible models to explain 
the inhibitory effect of the anti-/3~ antibody. (a) c~5/5~ com- 
plex binds transiently to the cell adhesive domain of fibro- 
nectin causing it to unfold and expose its aminoterminal do- 
main.  This initial binding to the cell adhesion domain is 
rapid but of  moderate affinity  that has been reported for bind- 
ing of soluble fibronectin to ceils in suspension (Akiyama 
and Yamada,  1984).  Such a  moderate affinity interaction 
might explain why no direct binding of iodinated fibronectin 
cell  adhesion  fragments  could  be  measured  (McKeown- 
Longo and Mosher,  1985) and why large amounts of unla- 
beled  cell  adhesion  fragments  are  required  to  compete 
fibronectin binding and matrix assembly (McDonald et al., 
1987;  our unpublished resultsg.  The anti-Bi  would there- 
fore block binding of soluble fibronectin to cell layers and 
its subsequent incorporation into the matrix by interfering 
with the initial transient binding event before the unfolding 
of the amino-terminal 70-kD domain. 
After fibronectin unfolds, the amino-terminal domain can 
bind  adjacent cell  surface  molecules,  including  adjacent 
fibronectin molecules.  This  binding  increases  the overall 
affinity of fibronectin binding and allows polymerization to 
begin.  A  possible role for fibronectin-fibronectin interac- 
tions in fibronectin binding to cell layers is supported by the 
finding that the amino-terminal region of horse fibronectin 
contains a  self-association site that can  interact with the 
carboxy-terminal regions of another fibronectin molecule in 
a head-to-tail manner (Ehrismann et al., 1982). The part of 
fibronectin mediating this interaction, however, is not in the 
most amino-terminal part of the protein but instead is proba- 
bly located in a region spanning the ninth type I homology 
and the adjacent first type III homology unit (Chernousov, 
M. A., E  J. Fogerty, V. E. Koteliansky, and D. F. Mosher, 
manuscript in preparation). This model, furthermore, does 
not explain how the anti-/3~ can block binding of the iso- 
lated 70-kD fragment. 
(b)  B~ complexed to an undetermined a  subunit (Otx) or 
conformationally changed ~Bm  may bind the non-RGDS- 
containing amino-terminal region (70 kD) of fibronectin to 
mediate binding of exogenous fibronectin and its incorpora- 
tion into the matrix. These are reasonable hypotheses to con- 
sider.  Increasing numbers of integrins are reported to bind 
other sequences besides or in addition to RGDS. Examples 
of Bm-containing integrins that bind  to  their  ligands in  a 
RGDS independent manner include VLA3 (c~3~t) binding 
to  fibronectin,  collagen,  and  laminin;  VLA1  (ohB~) and 
VLA2  (a2Bl)  binding  to  type  IV  and  type  I  collagen, 
respectively; and VLA4 (O~4~1) binding to fibronectin (Way- 
ner and Carter,  1987; Wayner et al.,  1988, 1989;  Kramer 
and Marks,  1989).  The hypothesis that a conformationally 
changed c~/3~ is required to bind the amino-terminal region 
of fibronectin is also feasible. Platelet glycoprotein 1  lb/11 la 
is one example of an integrin that must undergo a conforma- 
tional change before it can bind its ligands (Plow and Gins- 
berg,  1981). 
Cell attachment and spreading are probably mediated by 
the actin cytoskeleton that is linked to the integrins (Singer, 
1979, 1989; Tamkun et al., 1986; Horwitz et al., 1986; Ar- 
graves et al., 1989). The binding and assembly site for fibro- 
nectin is not present on ceils treated with cytochalasin (Barry 
and Mosher, 1988). Alterations in the actin cytoskeleton  that 
occur during cell attachment and spreading could potentially 
alter the conformation of the integrin receptor resulting in 
exposure of a unique 70-kD binding site. The requirement for 
a conformationally changed receptor would explain why we 
were not able to detect binding of detergent solubilized/3~- 
containing integrin to a 70 kD-Sepharose affinity column. 
In  this  second model  anti-/3t could inhibit binding be- 
cause of steric hindrance if the binding sites for the antibody 
and ligand were overlapping or adjacent. Alternatively, oc- 
cupancy of one binding site by anti-/3~ could produce a con- 
formational change in the receptor complex that would then 
preclude occupancy of the second binding site by the fibro- 
nectin or 70-kD fragment (Santoro and Lawing, 1987). 
(c)  o~5~ and/or o~x/3~ may recruit a  third component to 
form a binding site with specificity for the 70-kD region. The 
time that it takes the anti-/3t to uncouple the complex or to 
interfere with recruitment would explain why the inhibitory 
effect of anti-B~ lags behind the inhibitory effect of excess 
fibronectin. Higher concentrations of fibronectin would not 
be able to overcome the inhibitory effect of the antibody be- 
cause the antibody and fibronectin are not competing for the 
same binding site. The identity of the third component and 
the mechanism of the uncoupling are unknown. 
Cross-linking experiments indicate that the assembly of 
fibronectin  is  at  the  ends  of growing  fibrils  (Barry  and 
Mosher,  1989).  One effect of anti-o~5 and -B~ could be dis- 
sociation of the fibril ends  from assembly sites.  Another 
effect could be to block some modification or rearrangement 
of preexisting matrix that allows assembly to proceed. The 
assembly sites seem catalytic, and there must be a mecha- 
nism to regenerate the site, such as the endocytic cycle for 
~5~ reported by Bretscher (1989). This mechanism may re- 
quire cell locomotion. Interference with cycling could ex- 
plain the peculiar differences in distribution of o~5 and Bt af- 
ter incubation of fibroblasts with the monoclonal antibodies. 
In  conclusion,  our  finding that a  monoclonal antibody 
against the integrin B~ subunit completely blocks binding of 
the 70-kD amino-terminal fragment of fibronectin indicates 
that a B,-containing integrin is either directly or peripher- 
ally involved in the binding of the aminoterminal "matrix as- 
sembly domain" of soluble fibronectin to cell layers. Further 
studies should elucidate more precisely the role ~  integrins 
play in fibronectin matrix assembly. 
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